Eur Rev Med Pharmacol Sci 2019; 23 (8): 3326-3334

DOI: 10.26355/eurrev_201904_17695

MicroRNA-889 promotes cell proliferation in colorectal cancer by targeting DAB2IP

Y. Xiao, Z.-H. Li, Y.-H. Bi

Laboratory Medicine, Daqing Oilfield General Hospital, Daqing, China. 13658696216@163.com


OBJECTIVE: Colorectal cancer (CRC) remains one of the most frequent lethal malignant tumors worldwide. The correlation between miR-889 expression and CRC progression has not been well identified in the recent literature. Here, we aim to detect the role and mechanism of miR-889 in CRC.
PATIENTS AND METHODS: First, miRNA RT-PCR (Real Time-Polymerase Chain Reaction) was performed to determine miR-889 expression in CRC tissues and cells. The proliferative capacity of cells transfected with miR-889 mimics, miR-889 inhibitor or NC was measured by CCK-8 (cell counting kit-8), colony formation and EdU (5-Ethynyl-2’-deoxyuridine) assays. The online bioinformatics sites were chosen to predict possible downstream regulatory genes of miR-899. The dual-luciferase report assay was conducted to verify the relation between DAB2IP (DAB2 interacting protein) and miR-899. The expression changes of DAB2IP were assessed by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blot.
RESULTS: MiR-889 was upregulated in CRC tissues and CRC cells, and upregulated miR-889 was confirmed to promote cell growth in vitro. Dual-luciferase reporter, qRT-PCR, and Western blot assays suggested that DAB2IP might be regulated by miR-889. The effects of miR-889 on proliferation could be abolished by DAB2IP through confirmatory experiments. By directly targeting DAB2IP, miR-889 served as a vital part in accelerating CRC cell proliferation.
CONCLUSIONS: Our current study substantiated that miR-889 might participate in controlling CRC proliferation by regulating DAB2IP, which provides potential and prospective therapeutic target for CRC.

Free PDF Download

To cite this article

Y. Xiao, Z.-H. Li, Y.-H. Bi
MicroRNA-889 promotes cell proliferation in colorectal cancer by targeting DAB2IP

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 8
Pages: 3326-3334
DOI: 10.26355/eurrev_201904_17695